Depomed Inc. (DEPO)

7.41
NASDAQ : Health Technology
Prev Close 7.41
Day Low/High 0.00 / 0.00
52 Wk Low/High 4.31 / 17.30
Avg Volume 1.32M
Exchange NASDAQ
Shares Outstanding 62.96M
Market Cap 468.44M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Depomed is Now Oversold (DEPO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Depomed Breaks Above 200-Day Moving Average - Bullish for DEPO

In trading on Thursday, shares of Depomed Inc crossed above their 200 day moving average of $8.57, changing hands as high as $8.58 per share. Depomed Inc shares are currently trading up about 2.8% on the day.

Depomed Announces Closing Of NUCYNTA Commercialization Agreement With Collegium Pharmaceutical

Depomed Announces Closing Of NUCYNTA Commercialization Agreement With Collegium Pharmaceutical

Closing Triggers Upfront $10 Million Payment to Depomed

Depomed Reaches Analyst Target Price

In recent trading, shares of Depomed Inc have crossed above the average analyst 12-month target price of $8.14, changing hands for $8.53/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Skyworks Solutions Is 1 of 5 Big Stocks Ready to Abruptly Change Direction

Skyworks Solutions Is 1 of 5 Big Stocks Ready to Abruptly Change Direction

These names are showing bullish or bearish reversal patterns that occurred over the past week.

These Are the Biggest Winners and Losers in Activist Investing This Year

These Are the Biggest Winners and Losers in Activist Investing This Year

TheStreet recounts the successes and failures of the biggest names in the activism game.

First Week of June 2018 Options Trading For Depomed (DEPO)

Investors in Depomed Inc saw new options begin trading this week, for the June 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Depomed Announces Appointment Of Santosh J. Vetticaden, M.D., PH.D. As Senior Vice President, Chief Medical And Scientific Officer

Depomed Announces Appointment Of Santosh J. Vetticaden, M.D., PH.D. As Senior Vice President, Chief Medical And Scientific Officer

25 Year Pharmaceutical and Biotechnology Industry Executive Joins Senior Management Team

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Depomed, Inc. (DEPO)

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Depomed, Inc. (DEPO)

Glancy Prongay & Murray LLP ("GPM") reminds investors of the October 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Depomed, Inc.

Relative Strength Alert For Depomed

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of October 17th Lead Plaintiff Deadline In Securities Class Action Against Depomed, Inc. (DEPO)

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of October 17th Lead Plaintiff Deadline In Securities Class Action Against Depomed, Inc. (DEPO)

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that October 17, 2017, is the deadline to move for lead plaintiff status in the...

DEPOMED INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Depomed, Inc. To Contact The Firm

DEPOMED INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Depomed, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Depomed, Inc.

Relative Strength Alert For Depomed

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Depomed, Inc. Of Class Action Lawsuit And Upcoming Deadline - DEPO

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Depomed, Inc. Of Class Action Lawsuit And Upcoming Deadline - DEPO

Pomerantz LLP announces that a class action lawsuit has been filed against Depomed, Inc.

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Depomed, Inc. Shareholders And A Lead Plaintiff Deadline Of October 17, 2017

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Depomed, Inc. Shareholders And A Lead Plaintiff Deadline Of October 17, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Depomed, Inc.

DEPO INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Depomed, Inc. And A Lead Plaintiff Deadline Of October 17, 2017

DEPO INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Depomed, Inc. And A Lead Plaintiff Deadline Of October 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Depomed, Inc.

TheStreet Quant Rating: D (Sell)